Place de l'association de l'anticorps monoclonal anti-CD20 avec les agents immunomodulateurs.
(2004) Pathologie et Biologie — Vol. 52, n° 1, p. 39-42 (2004)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Chimeric monoclonal anti-CD20 antibody (Rituximab) has been associated with immunomodulatory agents such as interferon alpha, interleukin-2, interleukin-12, G-CSF, GM-CSF and anti-CD22 humanized monoclonal antibody (Epratuzumab). Synergy with interferon is clearly demonstrated increasing complete response rate and response duration. Other associations are promising but must be tested in randomized prospective trials versus rituximab alone, probably in indolent lymphomas where chemotherapy could be avoided.
- Affiliations
Citations
Bosly, A. (2004). Place de l’association de l’anticorps monoclonal anti-CD20 avec les agents immunomodulateurs. Pathologie et Biologie, 52(1), 39-42. https://doi.org/10.1016/S0369-8114(03)00051-8 (Original work published 2004)